Which Is A Better Pick: JNJ Stock Or AbbVie? [Forbes]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Forbes
SOPA Images/LightRocket via Getty Images Given its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings. However, we think that the new drugs that are gaining market share will drive a gap in valuation in favor of ABBV over the coming years. There is more to the comparison, and in the sections below, we discuss why we think ABBV will outperform JNJ in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation. 1. AbbVie Stock Has Outperformed JNJ ABBV stock has seen strong gains of 85% from levels of $90 in early January 2021 to around $165 now, vs. an increase of about 10% for JNJ over this period. In comparison, the broader S&P500 index is up 55% over this roughly four-year period. However, the changes in these stocks have been far from consistent. Returns for ABBV stock were 32
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy [Yahoo! Finance]Yahoo! Finance
- Dr Oz nominated to lead CMS despite big pharma ties [Yahoo! Finance]Yahoo! Finance
- Ophthalmic Equipment Market Size to Hit USD 105.20 Billion by 2033 | Straits Research [Yahoo! Finance]Yahoo! Finance
- EcoVadis' Coupa Connector Empowers Procurement Teams to Embed Sustainability into Every Purchasing Decision [Yahoo! Finance]Yahoo! Finance
- Dr. Oz Held Millions In Healthcare Investments, Raising Potential Conflicts For Medicare And Medicaid [Forbes]Forbes
JNJ
Earnings
- 10/15/24 - Beat
JNJ
Sec Filings
- 11/13/24 - Form 13F-HR
- 11/6/24 - Form 25-NSE
- 10/31/24 - Form 4/A
- JNJ's page on the SEC website